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1  | INTRODUC TION
Obesity is a rising global epidemic.Excess adiposity poses a tre-
mendous global public health burden in part due to the multitude 
of associated comorbidities including hypertension, diabetes 
mellitus (DM) and dyslipidemia.1 This constellation of disorders 
(ie, the metabolic syndrome) substantially increases the risk for 
cardiovascular morbidity and mortality as well as several other 
diseases.2-5 Unfortunately, the prevalence of the metabolic syn-
drome, currently impacting ~20% of the population, is only ex-
pected to increase.6
Due to shared risk factors (eg, obesity), the prevalence of obstruc-
tive sleep apnea (OSA) among patients with the metabolic syndrome 
often exceeds 50%—with the association becoming stronger as OSA 
severity increases.7 Moreover, the underlying pathophysiology (eg, 
insulin resistance, sympathetic overactivity, impaired exercise ca-
pacity) of OSA and the metabolic syndrome significantly overlaps, 
worsening cardiovascular function.8,9 To help combat the mounting 
obesity epidemic, a number of lifestyle changes (eg, weight loss) ca-
pable of improving both OSA and the metabolic syndrome are com-
monly recommended.10-13 In small studies, the positive impact of 
lifestyle changes on nerve reflex function was observed regardless 
of OSA status.14,15 However, it is plausible that larger studies may not 
reveal similar findings. We hypothesized that perturbations in nor-
mal metabolic processes, as well as poor sleep, daytime somnolence, 
and impaired exercise capacity could serve to thwart the benefits of 
lifestyle interventions. As such, we investigated if OSA influences 
the cardiometabolic benefits, with a focus on blood pressure (BP) 
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Obstructive sleep apnea (OSA) commonly coexists with the metabolic syndrome, a 
condition for which behavioral changes are often prescribed. Whether OSA dimin-
ishes the cardiometabolic health benefits from lifestyle interventions remains un-
clear. We evaluated 278 consecutive metabolic syndrome participants enrolled in a 
12-week comprehensive lifestyle intervention program. The changes in blood pres-
sure (BP), along with other metabolic health parameters, from baseline to follow-up 
were compared between those with and without OSA. Mean age was 52.4 ± 10.9 years 
and 37% were male. At enrollment, mean body mass index (BMI) was 38.2 ± 7.7 kg/
m2. OSA was reported in 126 of 269 final participants (47%). At baseline, participants 
with reported OSA were more likely to be male, older, have a higher BMI, waist and 
neck size (all P < 0.05). At program completion, participants with (−5.8 ± 16.1/ 
−3.0 ± 10.0 mm Hg) and without OSA (−4.7 ± 13.1/−3.3 ± 8.2 mm Hg) had signifi-
cant reductions in systolic and diastolic BP as well as BMI, fasting glucose, and tri-
glyceride levels. There were no significant differences in the absolute or percentage 
changes in BP or other metabolic parameters between groups. Our findings support 
that patients with the metabolic syndrome can derive substantial health benefits, 
including reductions in BP, by a lifestyle intervention program regardless of the pres-
ence of OSA.
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reductions, from a 12-week lifestyle intervention program in large 
group of patients with the metabolic syndrome.
2  | METHODS
The Metabolic Fitness Program (MetFit) is a prospective, nonran-
domized, unblinded, lifestyle intervention program targeting the 
metabolic syndrome.13 Participants are physician referred with com-
ponents of the metabolic syndrome as defined using American Heart 
Association (AHA)/NCEP ATP III. Informed consent was obtained on 
all participants as approved by the University of Michigan Medical 
School Institutional Review Board. This current study represents a 
post hoc observational analysis from the data collected as part of 
the MetFit program. Our objective was to determine if OSA status 
influences the cardiometabolic health benefits, with a specific focus 
on the degree of BP reductions.
2.1 | Patient assessment
Upon enrollment each participant was evaluated by a nurse practi-
tioner. The baseline assessment includes a medical history, fasting 
laboratory tests, as well as weight, waist, and neck circumference. 
BP was measured in the right and left arms in a seated position with 
arm elevated to the level of the heart. Reported blood pressures are 
the highest of the two arms. Symptom-limited exercise testing was 
performed in participants prior to initiating the exercise program if 
indicated following AHA standards.16 Patient assessments, less the 
symptom-limited stress test, are repeated at 12 weeks.
2.2 | Program
The MetFit program is a 12-week program that utilizes 90-min-
ute sessions once weekly in a cardiac rehabilitation setting.9 Each 
session includes 45 minutes of group education on cardiovascular 
risk factor reduction strategies including nutrition, stress manage-
ment, and exercise. The remaining portion of each weekly session is 
staff-guided aerobic exercise and group exercise consisting of circuit 
training, stretching, balance, and strengthening exercises.
2.3 | Exercise content
Prior to the first session, each participant had an individualized 
exercise consultation with an exercise physiologist (ACSM-CEP). 
The exercise physiologist reviews the fundamentals of an exercise 
program, barriers to participation, encourages basic goal setting, 
and crafts an initial exercise prescription. Exercise intensity was in-
dividually prescribed based on the symptom-limited stress test (if 
available) and provided as 60%-85% maximum heart rate achieved 
(Karvonen formula), ratings of perceived exertion (BORG), and 
symptoms or orthopedic limitations. Recommendations for exercise 
include progression from 150 to 300 minutes per week of a combi-
nation of moderate and vigorous intensity aerobic activity.17
2.4 | Nutrition content
The nutrition component of MetFit is based on a Mediterranean food 
pattern high in fruits, vegetables, heart-healthy fats, and soluble 
fiber. The education is designed to give participants the information 
needed to optimize their nutrition choices for improved cardiometa-
bolic parameters, as well as for weight loss of about 5% at 12 weeks 
(if appropriate). Each participant receives a baseline caloric intake 
estimate based on basal metabolic rate estimates created by the 
registered dietitian and reviewed on the first session. Depending on 
each participant’s level of physical activity the basal metabolic rate 
is increased by an activity factor to obtain daily intake needs. An 
in-house, nonvalidated, food frequency questionnaire is obtained 
by each participant to assess adherence to the Mediterranean food 
pattern.
2.5 | Sleep assessment
During the initial assessment, patients indicated if they had a his-
tory of OSA and what if any treatment had been prescribed. Medical 
record review validated the clinical status of OSA. Patients were ex-
cluded if medical record review was inconsistent with data obtained 
during the history and physical assessment. No polysomnogram 
data were used in this observational study, and as such, severity and 
treatment status were not evaluated.
2.6 | Statistical methods
The Student t tests were used to compare the means in physiologic 
measures between OSA groups at baseline. Paired t tests and the 
Student t test were used to examine if there was a statistically sig-
nificant difference in the changes of physiologic measures within 
the OSA and non-OSA groups and the difference in the change be-
tween each of the two groups. A P-value of <0.05 was used to deter-
mine statistical significance. Data were analyzed using SAS 9.3 (SAS 
Institute Inc, Cary, NC, USA).
3  | RESULTS
A total of 278 consecutive metabolic syndrome patients enrolled in 
a 12-week lifestyle intervention program (Figure 1). Reported OSA 
(n = 126, 47%) was verified by medical record review. Nine par-
ticipants were excluded after OSA status was unable to be verified 
through medical record review. Among the participants, 143 did not 
report a diagnosis of OSA.
Baseline demographics, biometrics, laboratory assays and the 
differences based on reported OSA status are listed in Table 1. More 
than 89% participants were obese (BMI ≥30 kg/m2). Program par-
ticipants attended 8.7 ± 3.1 of 12 exercise sessions and 8.5 ± 3.3 
of 12 education sessions. Reported OSA status did not impact the 
frequency of participation. Participants who reported a diagnosis of 
OSA were older, more likely to be male, have a larger BMI, waist and 
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neck size. Baseline systolic but not diastolic BP was higher in the 
OSA group (Table 1).
Many cardiometabolic health parameters improved in both 
groups following the 12-week lifestyle intervention (Tables 1 
and 2). For the entire cohort, mean weight loss at 12 weeks was 
2.9 ± 3.5 kg and 40.9% lost more than 5% of their body weight. For 
the main study outcome, average systolic and diastolic BP readings 
fell significantly in the entire cohort (−5.2 ± 14.6/−3.1 ± 9.0 mm Hg). 
Participants with (−5.8 ± 16.1/−3.0 ± 10.0 mm Hg) and without OSA 
(−4.7 ± 13.1/−3.3 ± 8.2 mm Hg) had significant reductions in both 
systolic and diastolic BP levels. Importantly, the magnitude of de-
creases in BP did not differ between groups (Table 2). Given the dif-
ferences in baseline values, we also evaluated the percentage change 
in BP between groups—which also did not significantly differ. In the 
mixed model analysis, there was no effect modification on the de-
gree of BP reduction by OSA status. At program completion, signifi-
cantly lower average and percent weight, BMI, and waist size were 
observed—which were not impacted by OSA status (Table 1). There 
were numerous additional improvements in cardiometabolic health 
parameters—none of which were lessened in the OSA group (Table 1).
4  | DISCUSSION
Our main finding was that while OSA was common among metabolic 
syndrome patients, it did not negatively impact the cardiometabolic 
health benefits derived from a comprehensive lifestyle intervention 
program. Importantly, BP levels were significantly reduced after 12-
weeks by a similar degree in both patients with and without OSA. 
Our findings are important because they support that health care 
providers should recommend to their patients with the metabolic 
syndrome to undertake these effective lifestyle changes—even in 
the presence of OSA.
MetFit is an outpatient lifestyle intervention program designed 
to help patients with the metabolic syndrome adopt sustainable life-
style modifications and behavior change targeting improved phys-
iologic, metabolic and biochemical profiles, and weight reduction. 
OSA was highly prevalent among MetFit participants (eg, nearly 
50%) which is not unexpected given the shared underlying risk fac-
tors (ie, obesity).18 OSA was associated with a larger BMI, greater 
waist and neck circumferences, and higher insulin levels compared 
to those without reported OSA. Despite modestly worse baseline 
metabolic parameters, patients with reported OSA derived similar 
overall cardiometabolic health benefits from a comprehensive life-
style intervention program.
Observed anthropometric and biochemical changes were simi-
lar to previous short-term lifestyle interventions.19 Improvement in 
average weight loss was not as significant as programs that included 
meal replacement.20 Systolic and diastolic BP response to weight 
loss were in expected range of 1 mm Hg reduction per kilogram of 
weight loss.21 In our study, gender and OSA status did not impact 
program participation. Therefore, the observed change in metabolic 
parameters was not influenced by the degree of participation as 
measured by session attendance.
Excess weight and OSA are commonly associated. Both randomized 
and nonrandomized weight loss trials have improved nocturnal events 
among those with OSA, but rarely prove to eliminate apneas com-
pletely.12 Here, we evaluated whether the presence of OSA diminishes 
the effectiveness of a lifestyle intervention program. This is a plausible 
hypothesis since perturbations in normal metabolic processes, as well as 
poor sleep, daytime somnolence, and impaired exercise capacity could 
serve to thwart the benefits. However, we found no such evidence. 
F I G U R E  1   Flowchart of the study. 
Among the nine participants excluded, the 
diagnosis of OSA could not be verified. 
Reasons included inability to communicate 
with referring physicians, lack of 
electronic medical record interoperability, 
or refusal to cooperate. OSA, obstructive 
sleep apnea
278 Consecutive Metabolic Fitness 
Participants
135 participants self-reported having 
obstructive sleep apnea
143 participants self-reported not having 
obstructive sleep apnea
9 participants unable to verify diagnosis of OSA 
based on chart review
EXCLUDED
126 participants with chart verified OSA
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Hence, the main clinical message from our findings is that OSA should 
not dissuade health care providers from recommending lifestyle in-
tervention programs to their patients with the metabolic syndrome. 
Indeed, the presence of OSA should not add to the list of barriers al-
ready known to dissuade patients from enrolling in these programs.22
Our findings are derived from a post hoc observational analysis of 
the MetFit program and therefore would benefit from corroboration 
in a randomized trial. Nevertheless, the sample size of our study was 
relatively large, and we found no evidence to support even minor dif-
ferences in health benefits between groups. Even if OSA does in fact 
Characteristics
All participants 
(n = 269)
Reported OSA status
Negative 
(n = 143)
Positive 
(n = 126) P‐value
Demographics
Mean age, years 52.4 (10.9) 49.9 (11.6) 55.4 (9.3) <0.0001
Female sex, % 168 (62.9) 97 (67.8) 71 (56.4) 0.052
White race,% 231 (8686) 117 (82.4) 114 (91.9) 0.02
Weight, kg 109.7 (24.2) 105.0 (21.4) 115.0 (26.1) 0.0006
BMI, kg/m2 38.2 (7.7) 36.9 (7.6) 39.7 (7.6) 0.003
Waist, cm 116.5 (15.7) 112.5 (14.1) 120.9 (16.4) <0.0001
Neck size, cm 40.5 (5.0) 39.3 (3.9) 41.9 (5.8) <0.0001
Blood pressure
Systolic BP, mm Hg 121.8 (16.4) 119.1 (14.9) 124.9 (17.6) 0.004
Diastolic BP, mm Hg 73.6 (9.5) 73.6 (9.4) 73.5 (9.7) 0.9
Metabolic lab parameters
Glucose, mg/
dL—Non-DM
100.5 (10.1) 99.8 (10.0) 101.3 (10.4) 0.3
Glucose, mg/dL—DM 155.5 (54.4) 148.5 (45.1) 163.0 (62.8) 0.2
Hgb A1c, % 6.3 (1.2) 6.3 (1.3) 6.4 (1.1) 0.8
Fasting INS, µmol/
mL—Non-DM
16.5 (9.8) 15.5 (9.2) 17.7 (10.4) 0.1
HOMA-IR—NonDM 4.1 (2.6) 3.9 (2.5) 4.5 (2.7) 0.1
LDL-C, mg/dL 105.7 (32.9) 107.4 (32.6) 103.9 (33.3) 0.4
HDL-C, mg/dL 46.2 (12.2) 47.3 (11.6) 45.0 (12.7) 0.1
TG, mg/dL 182.8 (107.6) 181.6 (110.3) 184.2 (104.9) 0.8
Data are given as number (%); or mean ± SD P-value represents a comparison of the negative vs posi-
tive OSA demographics.
BP, blood pressure; C, cholesterol; HDL, high-density lipoprotein; Hgb, Hemoglobin; HOMA-IR, 
Homeostatic Model Assessment of Insulin Resistance; INS, insulin; LDL, low-density lipoprotein; 
OSA, obstructive sleep apnea; TG, triglycerides.
TA B L E  1   Baseline health parameters 
for metabolic fitness participants
TA B L E  2   Change in blood pressure following lifestyle intervention
Characteristics
Reported OSA status
Comparison between 
OSA groupsNegative (n = 143) Positive (n = 126)
BL 12 wk
BL to 12 wk 
P‐value* BL 12 wk
BL to 12 wk 
P‐value* P‐value¶
Systolic BP, mm Hg 119.1 (14.9) 115.6 (14.8) 0.0003 124.9 (17.6) 119.6 (15.4) 0.001 0.6
Diastolic BP, mm Hg 73.6 (9.4) 70.8 (9.0) <0.0001 73.5 (9.7) 69.9 (8.7) 0.006 0.8
Comparison of change in blood pressure at 12-wk follow-up based on OSA presentation.
Data are given as number (%); or mean ± SD.
BL, baseline; DBP, diastolic blood pressure; OSA, obstructive sleep apnea; SBP, systolic blood pressure.
*P-value represents a comparison of the baseline vs 12-wk treatment results. 
¶P-value represents a comparison of the change in BP in OSA compared to the change in BP in the non-OSA group. 
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have a negative impact, we believe our results support that any true 
differences would be rather modest and not likely of clinical relevance. 
Motivational bias by self-pay may well have influenced the outcome and 
may prohibit generalizability to lower socioeconomic groups. The pres-
ence and severity of OSA in our study population was not universally 
assessed with a sleep study, thus the findings are not fully generalizable. 
Therefore, our study is unable to comment whether mild OSA benefited 
from lifestyle intervention more or less than severe OSA. However, clin-
ical and biochemical characteristics measured were taken from a large 
sample size, giving our conclusions strength. An additional limitation 
was the lack of medical record review to confirm negative OSA status 
with the participant’s initial self-report. It is possible that occult OSA 
was present in some patients without reported OSA. Finally, one final 
limitation is treatment status and compliance with prescribed treatment 
was not assessed, so we are careful not to overreach our conclusions.
5  | CONCLUSIONS
Lifestyle interventions targeting components of the metabolic syn-
drome are helpful in reducing BP and other cardiometabolic health 
parameters even in patients with OSA. Health care providers should 
strongly recommend that their patients with the metabolic syn-
drome undergo formal comprehensive lifestyle programs whenever 
possible, regardless of the presence of OSA.
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